{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-skin-infection-body-groin/prescribing-information/oral-griseofulvin/","result":{"pageContext":{"chapter":{"id":"0a620672-cf78-5a49-83c9-b25a3860e2b9","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin","depth":2,"htmlHeader":"<!-- begin field 9417f24e-acfa-4294-b102-a8d4013ecb98 --><h2>Oral griseofulvin</h2><!-- end field 9417f24e-acfa-4294-b102-a8d4013ecb98 -->","summary":"","htmlStringContent":"<!-- begin item 7aa3decf-a287-46b2-a338-a8d4013ecadd --><!-- end item 7aa3decf-a287-46b2-a338-a8d4013ecadd -->","topic":{"id":"10689662-2594-5bc5-aacc-6f0297698637","topicId":"0a9103d8-0e5e-4e22-8ed1-df6caa2888c6","topicName":"Fungal skin infection - body and groin ","slug":"fungal-skin-infection-body-groin","lastRevised":"Last revised in May 2018","chapters":[{"id":"f9a7dce7-311f-5a13-b2c1-c8cd43e2838e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"38743423-24de-522e-95bd-4e728ae9bff6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1f4590f4-eb5c-5ac7-ae22-883e2e53a6ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"9df03477-c55a-5aee-a960-67b35e299585","slug":"changes","fullItemName":"Changes"},{"id":"ef4d507c-dbca-5b25-8c50-9054ba69b8a6","slug":"update","fullItemName":"Update"}]},{"id":"6a5be767-a22b-5a75-9497-6b23cdd8af40","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3333af1c-9f09-5390-98b9-e6486fea24ad","slug":"goals","fullItemName":"Goals"},{"id":"181bd2da-6331-5aa0-a497-5c0924b85b3d","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"997df680-1de7-5ca8-bd57-bfdc04fc5708","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4c32deb8-71c7-5ff4-8ea7-21d5afcf46f0","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"291e3f39-4ba8-5287-b429-ab9096f614d1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"7b7795b7-aa4b-5d16-9865-1f78a9aa7100","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"aa83eccd-4445-5d6a-85eb-2ec1398484cd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2993ff5f-d929-5124-b985-8bfe992b6123","slug":"definition","fullItemName":"Definition"},{"id":"e4bd4185-0aa9-5252-9ab8-9db4872de8e3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"3b35bce6-3614-5272-b2bc-7dfec9933540","slug":"prevalence","fullItemName":"Prevalence"},{"id":"c9f8364f-4629-5bf0-9e81-6b5bc8fa4dc9","slug":"complications","fullItemName":"Complications"},{"id":"db007724-80ee-5dd6-bb25-70aa7c0fa306","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ddd3b119-1a06-5a24-a5c0-5bd1bdf86d33","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a8efce2f-87d2-504f-a1d5-92cbd6d2e262","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"aa17d36a-2510-5bdd-b47b-2b2182e55fb9","slug":"assessment","fullItemName":"Assessment"},{"id":"625c3efb-8f3e-5c3f-9743-9fb04531f418","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"ad2cfebe-3930-561d-8516-fccbfb956fbb","fullItemName":"Management","slug":"management","subChapters":[{"id":"058eae7f-c108-5ee2-9421-bce49270bd1d","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"33c2524f-5b03-5298-b8b3-38f522d33ee3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"3f5f1a54-036e-5ade-823a-9bc062fe3b65","slug":"topical-antifungals","fullItemName":"Topical antifungals"},{"id":"eb246451-6fc8-5e1c-af81-c0780be4ee3f","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"118430c7-7a53-56e6-a43c-ee7b3140563a","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"0a620672-cf78-5a49-83c9-b25a3860e2b9","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"}]},{"id":"6118e788-fa21-5752-864e-3f16ec7b305d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"bd6404d9-1abd-5cf0-99ee-b22f9fd18a84","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b7837228-7495-51a3-8ea2-973b7ec42868","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"9bbac54b-39fb-522f-bfc7-ce8158baf074","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3c0e56a8-bb2e-5a9e-acbf-0fd43dda553c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f92ac5d0-593d-5b61-887b-d0be3a924870","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ececdb26-b868-5c5c-834a-dd5d3bdef118","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ab97556e-8246-5384-b5eb-167898e7b53d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"33c2524f-5b03-5298-b8b3-38f522d33ee3","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"fcfeb6f2-329d-5638-9ada-0b8fa49b0830","slug":"dosing-schedule","fullItemName":"Dosing schedule","depth":3,"htmlHeader":"<!-- begin field 8d49aa6c-842f-4dfb-ad96-a8d4013ee1de --><h3>Dosing schedule</h3><!-- end field 8d49aa6c-842f-4dfb-ad96-a8d4013ee1de -->","summary":"","htmlStringContent":"<!-- begin item f515577a-118c-4843-8557-a8d4013ee13d --><!-- begin field a298a12e-f06e-4870-a64c-a8d4013ee1de --><ul><li>For adults, prescribe griseofulvin 500 mg daily, increased if necessary to 1000 mg daily for severe infections, for at least four weeks; reduce the dose when treatment response occurs.<ul><li>The daily dose may be taken once daily or in divided doses. Treatment should be continued for at least two weeks after lesions have healed.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">BNF 75, 2018</a>]</p><!-- end field a298a12e-f06e-4870-a64c-a8d4013ee1de --><!-- end item f515577a-118c-4843-8557-a8d4013ee13d -->","subChapters":[]},{"id":"5fb3d5d4-437d-5c04-99b8-b6c6bf49fd7d","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 7ae0b911-303a-4034-8671-a8d4013f2651 --><h3>Contraindications and cautions</h3><!-- end field 7ae0b911-303a-4034-8671-a8d4013f2651 -->","summary":"","htmlStringContent":"<!-- begin item c263d7d1-f710-4bae-be98-a8d4013f2590 --><!-- begin field 7ba6f2a4-fe7a-4469-a8f4-a8d4013f2651 --><ul><li><strong>Do not prescribe griseofulvin to people with:</strong><ul><li>Acute porphyria.</li><li>Severe liver disease.</li><li>Systemic lupus erythematosus — increased risk of exacerbation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">BNF 75, 2018</a>]</p><!-- end field 7ba6f2a4-fe7a-4469-a8f4-a8d4013f2651 --><!-- end item c263d7d1-f710-4bae-be98-a8d4013f2590 -->","subChapters":[]},{"id":"d35403d2-b6ee-536f-92c5-80b4c3a92ed3","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 2a532437-7262-4266-b7db-a8d4013f51f7 --><h3>Adverse effects</h3><!-- end field 2a532437-7262-4266-b7db-a8d4013f51f7 -->","summary":"","htmlStringContent":"<!-- begin item bbf8e380-437b-4d14-9b53-a8d4013f512d --><!-- begin field 7f6fa495-0824-4f7c-862e-a8d4013f51f7 --><ul><li><strong>Possible adverse effects of griseofulvin include:</strong><ul><li>Gastrointestinal — such as nausea, vomiting, diarrhoea, abdominal pain, dyspepsia, anorexia.<ul><li>Advise the person to take griseofulvin after a high-fat meal to increase systemic absorption and reduce the risk of adverse effects.</li></ul></li><li>Hepatobiliary — alteration in liver function tests (LFTs), intrahepatic cholestasis, and hepatitis.</li><li>Neuropsychiatric — headache, dizziness, confusion, taste disturbance, impaired co-ordination and hearing<strong>, </strong>peripheral neuropathy, sleep disturbances, agitation, and irritability.<ul><li>Advise the person that griseofulvin may enhance the effects of alcohol and impair the performance of skilled tasks, such as driving.</li></ul></li><li>Skin — rashes such as erythema multiforme, toxic epidermal necrolysis, photosensitivity, bullous reactions (including Lyell's syndrome), urticarial reactions.</li><li>Other — fatigue, leucopenia, neutropenia, anaemia (usually resolve on stopping treatment).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">BNF 75, 2018</a>] </p><!-- end field 7f6fa495-0824-4f7c-862e-a8d4013f51f7 --><!-- end item bbf8e380-437b-4d14-9b53-a8d4013f512d -->","subChapters":[]},{"id":"377d96fd-c9f3-5924-969c-d96cf0ab10cb","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 70dc06e1-16d2-4867-ba2d-a8d4013f7dcd --><h3>Drug interactions</h3><!-- end field 70dc06e1-16d2-4867-ba2d-a8d4013f7dcd -->","summary":"","htmlStringContent":"<!-- begin item 0eadd364-62e5-44e6-96e0-a8d4013f7d25 --><!-- begin field 6f4878f7-52d6-4646-b014-a8d4013f7dcd --><p><strong>Possible drug interactions with griseofulvin include:</strong></p><ul><li>Alcohol — concurrent use of alcohol and griseofulvin may cause a disulfiram-like reaction (flushing, tachycardia). Warn people about the possibility of this reaction.</li><li>Oral contraceptives — the efficacy of oral contraceptives may be reduced with concurrent griseofulvin use. The clinical significance of this effect is unknown.<ul><li>The Faculty of Sexual and Reproductive Healthcare (FSRH) recommends avoiding use of combined oral contraceptives (COCs) and progestogen-only contraceptives (POPs), the progestogen-only implant, and ulipristal acetate, and using an alternative method of contraception when using griseofulvin, and within 28 days of stopping treatment.<ul><li>If a woman wishes to use the COC when taking griseofulvin, consider an increased ethinylestradiol dose (at least 50 micrograms) during treatment and for a further 28 days after stopping griseofulvin, with a continuous or tricycling regimen plus pill-free interval of four days.</li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for more information.</li></ul></li></ul></li><li>Warfarin — griseofulvin potentially decreases the efficacy of warfarin. Monitor the international normalized ratio (INR), and adjust the anticoagulant dose accordingly. </li><li>Phenobarbital — may result in a decreased plasma level of griseofulvin, leading to a reduction in efficacy.</li><li>Primidone — may result in a decreased plasma level of griseofulvin, leading to a reduction in efficacy.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-body-groin/references/\">BNF 75, 2018</a>]</p><!-- end field 6f4878f7-52d6-4646-b014-a8d4013f7dcd --><!-- end item 0eadd364-62e5-44e6-96e0-a8d4013f7d25 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}